[Study of an efficacy and a pharmacokinetics of intranasal midazolam for status epilepticus on childhood epilepsy].
We reviewed the efficacy and a pharmacokinetics of intranasal midazolam (MDL) for status epilepticus in childhood epilepsies. This trial was planned for the patients who developed status epilepticus at least once in the past and had no responses with diazepam. Intranasal midazolam was proved to be effective (complete remission;65%), rapidly (an average time to stop seizures; 5.7 min) and safe with no adverse effects including respiratory depression with this dosage (an average of 0.26 mg/kg). In patients whose longitudinal concentrations of MDL in the blood were measured, MDL level was increased rapidly within five minutes after nasal application. Intranasal MDL is useful as a simple and safe method in the child emergency situation.